Figure 3.

Effect of HE3235 on growth of C4-2B in bone. (A) C4-2B cells were injected into tibiae of castrated male mice and when tumors were established half of the animals were treated with HE3235 (160 mg/kg) daily for 28 days. Left panel—HE3235 treatment resulted in decreases in weight of tumored tibiae suggesting inhibition of tumor growth while not exhibiting any significant effects on nontumored tibiae. Furthermore, HE3235-treated tumored tibiae weight was not significantly different as contralateral nontumored tibiae. Middle panel — HE3235 treatment caused alterations in serum PSA levels, which were significantly decreased at weeks 3 and 4 of the treatment (values are normalized to enrollment). *P < .001, ^#P < .10. Right panel—HE3235 treatment did not have any significant effects on BMD of tumored and nontumored tibiae. BMD was measured at the site of tumor-cell injection adjacent to the growth place. (B) Representative examples of H&E, PSA immunoreactivity, and radiographs of HE3235-treated and control tibiae are shown. Left panel — H&E staining show tumor growth in the bone marrow cavity next to the growth plate (located on the right-hand side). Multiple tumor foci are present between bone trabeculae secondary to the growth of this tumor in bone (magnification, x10). Middle panel — HE3235-treated tibiae show intensive PSA immunoreactivity (brown staining) in comparison to untreated tumored tibiae. Right panel — representative radiographs of tibia from each group.